NCT05677048Active, not recruiting
Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention
Source: ClinicalTrials.gov · Last updated 16 Sept 2026
Brief summary (registry, in English)
This is a community-based study requiring participant-self-enrollment, that can help to increase the rates of genetic testing among the family members of people who have been diagnosed with a hereditary cancer syndrome. The two main factors in this study are the IGNITE-TX intervention (website and navigator) and the free genetic counseling and testing. The IGNITE-TX Intervention is an innovative multi-modal intervention, with two components: a) interactive web "IGNITE-TX Hub" and b) genetic family navigators.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 205 (actual)
- First submitted
- 14 Dec 2022
- Start date
- 14 Apr 2023
- Primary completion date
- 31 Oct 2027
- Lead sponsor
- M.D. Anderson Cancer Center
- NCT number
- NCT05677048
What you commit to
- Study type: Interventional
- Participants enrolled: 205
- From 14 Apr 2023 to the primary completion date, 31 Oct 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Has no at-risk relatives meeting inclusion criteria
- Has negative germline genetic testing or only variant of uncertain significance
- Unwilling or unable to provide consent 4.2. AT-RISK RELATIVES (ARR)
- Unwilling or unable to provide consent
- Reports no known HBOC or LS variant within the family
- Has already been tested for the variant identified in the proband
- Already listed as an ARR for another proband
Who the study is looking for
- 18 years of age or older
- Speaks and/or reads English or Spanish
- Has known deleterious/pathogenic mutation or suspected deleterious/pathogenic variant in BRCA1 or BRCA2 (HBOC) or MLH1, MSH2, MSH6, PMS2, or EPCAM (LS)
- Has access to the internet or phone and can send and receive email and/or text messages at a US telephone number
- Has at least one at-risk relative who meets inclusion criteria for first-degree relative
- 18 years of age or older
- Speaks and reads English or Spanish
- Resides in the United States
- Can provide proof of deleterious/suspected deleterious HBOC or LS variant present in a first degree relative (biological mother or father, biological child, or full sibling)
- Has access to internet or phone and can send and receive email and/or text messages at a US telephone number
Criteria the registry did not label
- Probands
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| MD Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
Related publications
- A Multilevel Intervention to Identify Individuals for Genetic Testing and Treatment: The IGNITE-TX Pilot Randomized Clinical Trial.JAMA Netw Open · 2026 · PMID 42658496
This page is information, not medical advice. Discuss any trial with your doctor.